129791-91-9

Usage

Uses

1. Used in Pharmaceutical Industry:
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-10-(4-butylpiperazin-1-yl)-5,12,21,23-tetrahydroxy-27-methoxy-2,4,16,20,22,24,26-heptamethyl-1,6,15-trioxo-1,2-dihydro-6H,13H-2,7-(epoxypentadeca[1,11,13]trienoazeno)[1]benzofuro[4,5-a]phenoxazin-25-yl acet is used as a potential pharmaceutical candidate for various applications due to its complex structure and the presence of multiple functional groups that may interact with biological targets.
2. Used in Drug Delivery Systems:
The molecule can be employed in the development of novel drug delivery systems to enhance its applications and efficacy against specific biological targets. Various organic and metallic nanoparticles can be used as carriers for this molecule, aiming to improve its delivery, bioavailability, and therapeutic outcomes.
3. Used in Chemical Research:
Due to its unique structure and functional groups, this molecule can be used in chemical research to study its interactions with other molecules and to understand its potential applications in various fields, such as material science, catalysis, or environmental chemistry.

Upstream product

• 5610-49-1 N-butylpiperazine 
• 143526-61-8 3'-tert-butyldimethylsilyloxybenzoxazinorifamycin 
• 143526-60-7 2-amino-3-(tert-butyldimethylsilyloxy)phenol 
• 634-60-6 2-aminoresorcinol hydrochloride 
• 105396-63-2 3'-hydroxy-benzoxazinorifamycin 

Relevant academic research and scientific papers

Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins

We report herein the preparation and anti-staphylococcal activity of a series of novel 11-deoxy-11-hydroxyiminorifamycins. Many of the compounds synthesized exhibit potent activity against wild-type Staphylococcus aureus with MICs equivalent to, or better

Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives

As a part of our studies on the syntheses of benzoxazinorifamycin derivatives, 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives were synthesized, and tested for their antimicrobial activities. The antimicrobial activities of these compounds against gram-positive and gram-negative bacteria were almost identical to those of rifampicin (RFP) and rifabutain (RFB), however, antimicrobial activities against Mycobacterium tuberculosis were superior to RFP, while being similar to RFB. 3'-Hydroxy-5'-(4-alkyl-1-piperazinyl)benzoxazinorifamycin derivatives also had in vitro potent activities against Mycobacterium avium complex (MAC). Their minimal inhibitory concentration values against MAC were 2-256 times greater than RFP and RFB. Their in vivo efficacies against M. tuberculosis and MAC, after oral administration to mice, were superior to RFP and REB, except for RFB against M. tuberculosis activity in vivo. Although they were absorbed from the gastrointestinal tract, their plasma levels were lower than that of RFP. Among these 5'-(4-alkyl-1-piperazinyl) derivatives, 3'-hydroxy-5'-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin, compound 19 (KRM-1648), was selected as the most promising and its preliminary pharmacokinetic characteristics in mice were investigated. Compound 19 was distributed much more in tissues, especially in spleen and lung, than in plasma and had a long elimination time from tissues.